AKT1 and neoplasm: Since the PI3K-AKT-mTOR can also become activated in the absence of PIK3CA mutation, for example through loss of PTEN, or mutations in AKT and MTOR, it is hoped that the clinical activity of PI3K inhibitors may not be limited to PIK3CA mutant tumours.